Health Care and the 2008 Election: Revolution, Reform, or Return to Business as Usual?
As the presidential race heats up, health care executives say they have many reasons to be excited--and nervous. BCG reviews an industry-wide survey on the implications of the candidates' health care proposals for the pharma and device industries.
You may also be interested in...
Health care cost trends may not be so bad after all, former Obama advisor writes in New England Journal of Medicine. Prescription drugs can help, he writes-but not entirely in the way industry would hope.
Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.
Drug sponsors should use end-of-Phase 2A meetings for the in-depth discussions with FDA regarding dose estimation and selection that other pre-submission meetings do not allow for, according to a 1draft guidance